[{"orgOrder":0,"company":"Neutec Ar-Ge San ve Tic A.?","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cefdinir","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Neutec Ar-Ge San ve Tic A.?","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Neutec Ar-Ge San ve Tic A.? \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Cefdinir

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Neutec Ar-Ge San ve Tic A.?

                          Country arrow
                          AAPS
                          Not Confirmed

                          Neutec Ar-Ge San ve Tic A.?

                          Country arrow
                          AAPS
                          Not Confirmed

                          Details : Cefdinir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Bronchitis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 17, 2018

                          Lead Product(s) : Cefdinir

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank